On the public citation graph
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
0 signed · 328 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2021.1932openalex-snapshot
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer
inferredcites →https://doi.org/10.1002/anie.201106527openalex-snapshot
A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer Therapy
inferredcites →https://doi.org/10.1002/cac2.12207openalex-snapshot
Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020
inferredcites →https://doi.org/10.1002/cac2.12387openalex-snapshot
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
inferredcites →https://doi.org/10.1002/cncr.32392openalex-snapshot
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
inferredcites →https://doi.org/10.1002/ijc.30276openalex-snapshot
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer
inferredcites →https://doi.org/10.1002/ijc.30569openalex-snapshot
Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
inferredcites →https://doi.org/10.1002/ijc.32408openalex-snapshot
[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
inferredcites →https://doi.org/10.1002/prp2.617openalex-snapshot
Characterization of T‐DM1‐resistant breast cancer cells
inferredcites →https://doi.org/10.1007/s00280-014-2405-0openalex-snapshot
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
inferredcites →https://doi.org/10.1007/s10120-021-01168-7openalex-snapshot
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
inferredcites →https://doi.org/10.1007/s10549-010-1090-xopenalex-snapshot
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
inferredcites →https://doi.org/10.1007/s10549-015-3503-3openalex-snapshot
A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity
inferredcites →https://doi.org/10.1007/s10549-018-4792-0openalex-snapshot
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
inferredcites →https://doi.org/10.1007/s12282-018-0861-9openalex-snapshot
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
inferredcites →https://doi.org/10.1007/s13238-016-0323-0openalex-snapshot
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
inferredcites →https://doi.org/10.1007/s40265-020-01337-5openalex-snapshot
Sacituzumab Govitecan: First Approval
inferredcites →https://doi.org/10.1016/j.annonc.2020.06.020openalex-snapshot
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
inferredcites →https://doi.org/10.1016/j.annonc.2020.09.004openalex-snapshot
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
inferredcites →https://doi.org/10.1016/j.annonc.2021.05.524openalex-snapshot
O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*
inferredcites →https://doi.org/10.1016/j.annonc.2021.06.002openalex-snapshot
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.1036openalex-snapshot
514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.2085openalex-snapshot
LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.2087openalex-snapshot
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.2088openalex-snapshot
LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.542openalex-snapshot
259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.554openalex-snapshot
271P First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
inferredcites →https://doi.org/10.1016/j.annonc.2021.08.612openalex-snapshot
329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer
inferredcites →https://doi.org/10.1016/j.annonc.2022.03.184openalex-snapshot
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
inferredcites →https://doi.org/10.1016/j.apsb.2020.11.020openalex-snapshot
The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems
inferredcites →https://doi.org/10.1016/j.bcp.2015.12.008openalex-snapshot
Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
inferredcites →https://doi.org/10.1016/j.breast.2022.01.002openalex-snapshot
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
inferredcites →https://doi.org/10.1016/j.canlet.2016.08.026openalex-snapshot
Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells
inferredcites →https://doi.org/10.1016/j.canlet.2019.12.037openalex-snapshot
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
inferredcites →https://doi.org/10.1016/j.cbpa.2015.08.005openalex-snapshot
An emerging playbook for antibody–drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety
inferredcites →https://doi.org/10.1016/j.ccell.2015.12.008openalex-snapshot
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
inferredcites →https://doi.org/10.1016/j.ccell.2016.02.006openalex-snapshot
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
inferredcites →https://doi.org/10.1016/j.clbc.2021.03.005openalex-snapshot
A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy
inferredcites →https://doi.org/10.1016/j.ctrv.2021.102286openalex-snapshot
Targeting HER2 heterogeneity in breast cancer
inferredcites →https://doi.org/10.1016/j.ebiom.2019.04.061openalex-snapshot
Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1
inferredcites →https://doi.org/10.1016/j.ejca.2018.12.022openalex-snapshot
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
inferredcites →https://doi.org/10.1016/j.ijbiomac.2017.10.113openalex-snapshot
Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy
inferredcites →https://doi.org/10.1016/j.pharmthera.2019.04.008openalex-snapshot
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
inferredcites →https://doi.org/10.1016/j.trecan.2021.09.002openalex-snapshot
Chromosomal instability and aneuploidy as causes of cancer drug resistance
inferredcites →https://doi.org/10.1016/j.yrtph.2015.01.014openalex-snapshot
An FDA oncology analysis of antibody-drug conjugates
inferredcites →https://doi.org/10.1016/s0140-6736(19)31774-xopenalex-snapshot
Antibody–drug conjugates for cancer
inferredcites →https://doi.org/10.1016/s1470-2045(14)70178-0openalex-snapshot
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30312-1openalex-snapshot
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30313-3openalex-snapshot
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30716-7openalex-snapshot
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30097-xopenalex-snapshot
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
inferredcites →https://doi.org/10.1016/s1470-2045(19)30328-6openalex-snapshot
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
inferredcites →https://doi.org/10.1016/s1470-2045(20)30465-4openalex-snapshot
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
inferredcites →https://doi.org/10.1021/acs.bioconjchem.5b00223openalex-snapshot
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
inferredcites →https://doi.org/10.1021/bc900315yopenalex-snapshot
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
inferredcites →https://doi.org/10.1038/bjc.2017.367openalex-snapshot
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
inferredcites →https://doi.org/10.1038/modpathol.2012.36openalex-snapshot
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
inferredcites →https://doi.org/10.1038/nbt.1480openalex-snapshot
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
inferredcites →https://doi.org/10.1038/nrd.2016.268openalex-snapshot
Strategies and challenges for the next generation of antibody–drug conjugates
inferredcites →https://doi.org/10.1038/nri2155openalex-snapshot
FcRn: the neonatal Fc receptor comes of age
inferredcites →https://doi.org/10.1038/s41388-017-0108-9openalex-snapshot
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer
inferredcites →https://doi.org/10.1038/s41416-020-0952-1openalex-snapshot
YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
inferredcites →https://doi.org/10.1038/s41467-021-23793-7openalex-snapshot
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
inferredcites →https://doi.org/10.1038/s41467-021-26018-zopenalex-snapshot
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
inferredcites →https://doi.org/10.1038/s41467-021-26019-yopenalex-snapshot
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
inferredcites →https://doi.org/10.1038/s41523-021-00311-yopenalex-snapshot
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
inferredcites →https://doi.org/10.1038/s41573-019-0028-1openalex-snapshot
Bispecific antibodies: a mechanistic review of the pipeline
inferredcites →https://doi.org/10.1038/s41598-018-22250-8openalex-snapshot
Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells
inferredcites →https://doi.org/10.1038/s41598-019-48212-2openalex-snapshot
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
inferredcites →https://doi.org/10.1038/sj.onc.1207528openalex-snapshot
Cell death by mitotic catastrophe: a molecular definition
inferredcites →https://doi.org/10.1039/c8cs00676hopenalex-snapshot
Cleavable linkers in antibody–drug conjugates
inferredcites →https://doi.org/10.1042/bsr20150089openalex-snapshot
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
inferredcites →https://doi.org/10.1056/nejmoa1209124openalex-snapshot
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1814017openalex-snapshot
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1914510openalex-snapshot
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa2028485openalex-snapshot
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa2115022openalex-snapshot
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
inferredcites →https://doi.org/10.1083/jcb.201403127openalex-snapshot
A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination
inferredcites →https://doi.org/10.1091/mbc.e04-07-0591openalex-snapshot
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
inferredcites →https://doi.org/10.1093/abt/tbab017openalex-snapshot
Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors
inferredcites →https://doi.org/10.1093/annonc/mdw157openalex-snapshot
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
inferredcites →https://doi.org/10.1093/jnci/djv313openalex-snapshot
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
inferredcites →https://doi.org/10.1093/neuonc/noae123openalex-snapshot
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
inferredcites →https://doi.org/10.1111/cas.12966openalex-snapshot
Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
inferredcites →https://doi.org/10.1111/cas.13253openalex-snapshot
Aberrant intracellular metabolism of T‐ DM 1 confers T‐ DM 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells
inferredcites →https://doi.org/10.1111/cas.14898openalex-snapshot
Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models
inferredcites →https://doi.org/10.1111/imr.12349openalex-snapshot
Human IgG4: a structural perspective
inferredcites →https://doi.org/10.1111/j.1365-2141.2007.06883.xopenalex-snapshot
High CD21 expression inhibits internalization of anti‐CD19 antibodies and cytotoxicity of an anti‐CD19‐drug conjugate
inferredcites →https://doi.org/10.1111/jcmm.15643openalex-snapshot
Hsp90 inhibition and co‐incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T‐DM1
inferredcites →https://doi.org/10.1124/dmd.115.064253openalex-snapshot
Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker
inferredcites →https://doi.org/10.1124/jpet.110.168062openalex-snapshot
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
inferredcites →https://doi.org/10.1126/scitranslmed.aac4925openalex-snapshot
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
inferredcites →https://doi.org/10.1146/annurev-pathol-042020-042741openalex-snapshot
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
inferredcites →https://doi.org/10.1146/annurev-physiol-021014-071649openalex-snapshot
Lysosomal Physiology
inferredcites →https://doi.org/10.1158/0008-5472.can-08-1776openalex-snapshot
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
inferredcites →https://doi.org/10.1158/0008-5472.can-10-2277openalex-snapshot
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
inferredcites →https://doi.org/10.1158/0008-5472.can-15-1313openalex-snapshot
Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
inferredcites →https://doi.org/10.1158/0008-5472.can-15-1610openalex-snapshot
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
inferredcites →https://doi.org/10.1158/0008-5472.can-16-3127openalex-snapshot
Resistance to the Antibody–Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0358openalex-snapshot
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-0012openalex-snapshot
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-2035openalex-snapshot
A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-2499openalex-snapshot
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-2822openalex-snapshot
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-0970openalex-snapshot
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-2401openalex-snapshot
Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-0696openalex-snapshot
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-1300openalex-snapshot
SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-1745openalex-snapshot
A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-3757openalex-snapshot
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-4557openalex-snapshot
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-4740openalex-snapshot
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
inferredcites →https://doi.org/10.1158/1535-7163.mct-13-0896openalex-snapshot
SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-14-0862openalex-snapshot
Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
inferredcites →https://doi.org/10.1158/1535-7163.mct-14-0881-topenalex-snapshot
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
inferredcites →https://doi.org/10.1158/1535-7163.mct-15-0036openalex-snapshot
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0219openalex-snapshot
Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
inferredcites →https://doi.org/10.1158/1535-7163.mct-17-0296openalex-snapshot
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
inferredcites →https://doi.org/10.1158/1535-7163.mct-17-0403openalex-snapshot
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
inferredcites →https://doi.org/10.1158/1535-7163.mct-17-0749openalex-snapshot
A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
inferredcites →https://doi.org/10.1158/1535-7163.mct-18-0743openalex-snapshot
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
inferredcites →https://doi.org/10.1158/1535-7163.mct-19-0207openalex-snapshot
A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
inferredcites →https://doi.org/10.1158/1535-7163.mct-19-1004openalex-snapshot
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
inferredcites →https://doi.org/10.1158/1535-7163.mct-20-0014openalex-snapshot
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-20-0237openalex-snapshot
PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
inferredcites →https://doi.org/10.1158/1535-7163.mct-21-0206openalex-snapshot
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
inferredcites →https://doi.org/10.1158/1538-7445.sabcs14-p5-19-08openalex-snapshot
Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results
inferredcites →https://doi.org/10.1158/1538-7445.sabcs18-p6-17-13openalex-snapshot
Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
inferredcites →https://doi.org/10.1158/1538-7445.sabcs20-pd3-06openalex-snapshot
Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer
inferredcites →https://doi.org/10.1158/1538-7445.sabcs20-ps11-07openalex-snapshot
Abstract PS11-07: Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166
inferredcites →https://doi.org/10.1158/1541-7786.mcr-19-0856openalex-snapshot
Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
inferredcites →https://doi.org/10.1158/2159-8290.cd-20-0215openalex-snapshot
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
inferredcites →https://doi.org/10.1158/2159-8290.cd-20-1557openalex-snapshot
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
inferredcites →https://doi.org/10.1158/2159-8290.cd-21-0702openalex-snapshot
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1182/blood-2003-11-3825openalex-snapshot
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
inferredcites →https://doi.org/10.1182/blood-2009-02-205500openalex-snapshot
Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
inferredcites →https://doi.org/10.1186/s12885-019-5687-0openalex-snapshot
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
inferredcites →https://doi.org/10.1186/s13046-016-0433-9openalex-snapshot
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
inferredcites →https://doi.org/10.1186/s13058-014-0419-5openalex-snapshot
Dual HER2 blockade: preclinical and clinical data
inferredcites →https://doi.org/10.1186/s13058-017-0900-zopenalex-snapshot
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
inferredcites →https://doi.org/10.1186/s13058-019-1186-0openalex-snapshot
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
inferredcites →https://doi.org/10.1186/s13058-020-1252-7openalex-snapshot
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
inferredcites →https://doi.org/10.1200/edbk_280775openalex-snapshot
Antibody-Drug Conjugates: Patient and Treatment Selection
inferredcites →https://doi.org/10.1200/jco.19.00858openalex-snapshot
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
inferredcites →https://doi.org/10.1200/jco.19.00882openalex-snapshot
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
inferredcites →https://doi.org/10.1200/jco.19.01455openalex-snapshot
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
inferredcites →https://doi.org/10.1200/jco.19.02318openalex-snapshot
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
inferredcites →https://doi.org/10.1200/jco.19.02488openalex-snapshot
HER2-Low Breast Cancer: Pathological and Clinical Landscape
inferredcites →https://doi.org/10.1200/jco.2010.29.5865openalex-snapshot
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
inferredcites →https://doi.org/10.1200/jco.2016.67.4887openalex-snapshot
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.1035openalex-snapshot
Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.1039openalex-snapshot
A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.3551openalex-snapshot
First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.500openalex-snapshot
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.526openalex-snapshot
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.tps3659openalex-snapshot
SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
inferredcites →https://doi.org/10.1200/jco.2021.39.15_suppl.1024openalex-snapshot
Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
inferredcites →https://doi.org/10.1200/jco.2021.39.15_suppl.tps1108openalex-snapshot
NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial.
inferredcites →https://doi.org/10.1517/14712591003689972openalex-snapshot
HER2 as a target for breast cancer therapy
inferredcites →https://doi.org/10.18632/genesandcancer.211openalex-snapshot
Correction: CDK4/ 6 inhibition provides a potent adjunct to Her2- targeted therapies in preclinical breast cancer models
inferredcites →https://doi.org/10.18632/genesandcancer.24openalex-snapshot
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
inferredcites →https://doi.org/10.18632/oncotarget.27766openalex-snapshot
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
inferredcites →https://doi.org/10.2147/dddt.s149032openalex-snapshot
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
inferredcites →https://doi.org/10.3389/fphar.2019.00749openalex-snapshot
Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
inferredcites →https://doi.org/10.3390/biomedicines9111512openalex-snapshot
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
inferredcites →https://doi.org/10.3390/cancers12082081openalex-snapshot
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.3390/cancers9050040openalex-snapshot
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
inferredcites →https://doi.org/10.3390/ijms17040561openalex-snapshot
Linkers Having a Crucial Role in Antibody–Drug Conjugates
inferredcites →https://doi.org/10.3390/ijms21165626openalex-snapshot
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
inferredcites →https://doi.org/10.3390/ijms21186882openalex-snapshot
Design and Validation of Linkers for Site-Specific Preparation of Antibody–Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site
inferredcites →https://doi.org/10.3390/ph14070672openalex-snapshot
Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues
inferredcites →https://doi.org/10.4137/cmo.s18006openalex-snapshot
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
inferredcites →https://doi.org/10.4161/cc.3.1.607openalex-snapshot
The Achilles Heel of ErbB-2/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention
inferredcites →https://doi.org/10.4161/mabs.22854openalex-snapshot
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4855986openalex-extracted
Pharmacoepidemiology Study of Antibody-Drug Conjugate-Associated Interstitial Lung Disease
inferred← citeshttps://doi.org/10.1002/advs.202515498openalex-snapshot
Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer
inferred← citeshttps://doi.org/10.1002/cac2.12517openalex-snapshot
Development of antibody‐drug conjugates in cancer: Overview and prospects
inferred← citeshttps://doi.org/10.1002/cmdc.202400109openalex-snapshot
The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
inferred← citeshttps://doi.org/10.1002/cncr.35093openalex-snapshot
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
inferred← citeshttps://doi.org/10.1002/cncr.70417openalex-snapshot
Antibody–drug conjugates in gynecologic cancers
inferred← citeshttps://doi.org/10.1002/cpt.70341openalex-snapshot
Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs
inferred← citeshttps://doi.org/10.1002/inmd.70073openalex-snapshot
TROP2‐guided aggregation‐induced emission‐luminogen nanoparticles overcome sacituzumab govitecan resistance via mitochondrial oxidative stress and immunogenic cell death in triple‐negative breast cancer
inferred← citeshttps://doi.org/10.1002/mc.70115openalex-snapshot
Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers
inferred← citeshttps://doi.org/10.1002/ptr.8407openalex-snapshot
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
inferred← citeshttps://doi.org/10.1002/smll.75840openalex-snapshot
HER2‐Targeted AIE Nanotheranostics Overcome SHR‐A1811 Resistance via Immunogenic Pyroptosis and Tumor‐Associated Macrophage Reprogramming in Breast Cancer
inferred← citeshttps://doi.org/10.1002/sstr.202500846openalex-snapshot
Light‐Activated Multifunctional Nanoplatforms: Reshaping Combination Therapy to Overcome Multidrug Resistance in Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-981-95-6378-4_6openalex-snapshot
Small-Molecule Drug Discovery: Evolution of Medicinal Chemistry and Holistic Approaches
inferred← citeshttps://doi.org/10.1007/s00280-025-04848-8openalex-snapshot
Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions
inferred← citeshttps://doi.org/10.1007/s11427-025-3016-4openalex-snapshot
Development and application of antibody-drug conjugates in gynecological cancers
inferred← citeshttps://doi.org/10.1007/s11427-025-3311-5openalex-snapshot
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
inferred← citeshttps://doi.org/10.1007/s12282-026-01908-6openalex-snapshot
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s12672-024-01192-wopenalex-snapshot
Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis
inferred← citeshttps://doi.org/10.1007/s12672-025-01820-zopenalex-snapshot
Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
inferred← citeshttps://doi.org/10.1007/s12672-025-02457-8openalex-snapshot
Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges
inferred← citeshttps://doi.org/10.1007/s12672-025-03426-xopenalex-snapshot
Antibody-drug conjugates in triple-negative breast cancer (2010–2024): a bibliometric analysis of global trends and clinical translation
inferred← citeshttps://doi.org/10.1007/s12672-025-03764-wopenalex-snapshot
Decoding breast cancer: insights into molecular pathways & therapeutic approaches
inferred← citeshttps://doi.org/10.1007/s12672-026-04492-5openalex-snapshot
Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics
inferred← citeshttps://doi.org/10.1007/s12672-026-05240-5openalex-snapshot
KIF23 in disease pathogenesis and its therapeutic and diagnostic potential
inferred← citeshttps://doi.org/10.1007/s40265-026-02289-yopenalex-snapshot
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale
inferred← citeshttps://doi.org/10.1016/b978-0-443-21790-6.00006-7openalex-snapshot
Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome
inferred← citeshttps://doi.org/10.1016/j.apsb.2024.12.036openalex-snapshot
Resistance to antibody–drug conjugates: A review
inferred← citeshttps://doi.org/10.1016/j.apsb.2025.06.012openalex-snapshot
A dual-targeting peptide–drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.apsb.2026.03.004openalex-snapshot
Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models
inferred← citeshttps://doi.org/10.1016/j.apsb.2026.05.032openalex-snapshot
Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates
inferred← citeshttps://doi.org/10.1016/j.bbcan.2025.189369openalex-snapshot
Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions
inferred← citeshttps://doi.org/10.1016/j.bbcan.2025.189412openalex-snapshot
Reprogramming of amino acid metabolism in breast cancer
inferred← citeshttps://doi.org/10.1016/j.bioactmat.2025.06.034openalex-snapshot
Antibody-functionalized iron-based nanoplatform for ferroptosis-augmented targeted therapy of HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1016/j.blre.2025.101256openalex-snapshot
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
inferred← citeshttps://doi.org/10.1016/j.breast.2024.103830openalex-snapshot
Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104470openalex-snapshot
The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study
inferred← citeshttps://doi.org/10.1016/j.ccell.2026.05.003openalex-snapshot
When more target antigen expression is less
inferred← citeshttps://doi.org/10.1016/j.cej.2024.155709openalex-snapshot
Mechanism of Self-Assembled Celastrol-Erianin Nanomedicine for treatment of breast cancer
inferred← citeshttps://doi.org/10.1016/j.cej.2026.182176openalex-snapshot
A dual-payload heavy-chain antibody conjugate boosting bystander effect for heterogeneous tumor therapy
inferred← citeshttps://doi.org/10.1016/j.cell.2026.04.016openalex-snapshot
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
inferred← citeshttps://doi.org/10.1016/j.cpccr.2023.100258openalex-snapshot
Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.104205openalex-snapshot
Toxic warhead-armed antibody for targeted treatment of glioblastoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104624openalex-snapshot
Challenges and prospects in HER2-positive breast cancer-targeted therapy
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.105015openalex-snapshot
Antibody-drug conjugates in oncology: A spotlight on overcoming resistance
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2026.105179openalex-snapshot
Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.103067openalex-snapshot
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
inferred← citeshttps://doi.org/10.1016/j.drup.2024.101086openalex-snapshot
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
inferred← citeshttps://doi.org/10.1016/j.drup.2024.101126openalex-snapshot
crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
inferred← citeshttps://doi.org/10.1016/j.drup.2026.101447openalex-snapshot
Immunotherapy in cancer: Mechanisms and strategies to overcome resistance
inferred← citeshttps://doi.org/10.1016/j.esmoop.2025.105837openalex-snapshot
Expression of antibody–drug conjugate targets in soft tissue sarcomas
inferred← citeshttps://doi.org/10.1016/j.fmre.2024.02.021openalex-snapshot
The application of antibody-based agents in cancer therapy based on their mechanisms of action
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e41590openalex-snapshot
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2024.139443openalex-snapshot
Targeting HSP90AA1 to overcome multiple drug resistance in breast cancer using magnetic nanoparticles loaded with salicylic acid
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.140767openalex-snapshot
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
inferred← citeshttps://doi.org/10.1016/j.jconrel.2025.114165openalex-snapshot
Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy
inferred← citeshttps://doi.org/10.1016/j.jddst.2026.108271openalex-snapshot
From concept to clinic: Cutting-Edge advances steering the next wave of antibody–drug conjugates innovation
inferred← citeshttps://doi.org/10.1016/j.lfs.2024.122676openalex-snapshot
Antibody-drug conjugates: Principles and opportunities
inferred← citeshttps://doi.org/10.1016/j.omton.2024.200762openalex-snapshot
TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs
inferred← citeshttps://doi.org/10.1016/j.pharmr.2025.100087openalex-snapshot
Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy
inferred← citeshttps://doi.org/10.1016/j.resinv.2025.05.012openalex-snapshot
Mechanisms of resistance to antibody–drug conjugates in cancers
inferred← citeshttps://doi.org/10.1016/j.xcrm.2026.102769openalex-snapshot
Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling
inferred← citeshttps://doi.org/10.1016/j.ygyno.2025.03.013openalex-snapshot
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics
inferred← citeshttps://doi.org/10.1016/j.ymthe.2023.03.019openalex-snapshot
Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c00837openalex-snapshot
Development and Preclinical Evaluation of a Novel 68Ga/177Lu-Labeled Nanobody for Radiotheranostics of HER2-Positive Tumors
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.6c00316openalex-snapshot
An Innovative Strategy for the Redox Balance in Breast Cancer with Wool Keratin-Stabilized Copper Nanozyme
inferred← citeshttps://doi.org/10.1021/acsabm.5c02525openalex-snapshot
Alpha-Tocopherol-Conjugated DNA Tetrahedron with Enhanced Cellular Uptake and Cytotoxicity for Cancer Therapeutics
inferred← citeshttps://doi.org/10.1021/acsanm.4c04925openalex-snapshot
Hollow Mesoporous Selenium Nanoparticles Loaded with Pyrotinib and Coated with Trastuzumab-Functionalized Albumin for Targeted Therapy of HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1021/mc-2025-vol60.ch11openalex-snapshot
ANTIBODY-DRUG CONJUGATES IN ONCOLOGY: RECENT ACHIEVEMENTS AND CURRENT CHALLENGES
inferred← citeshttps://doi.org/10.1038/s41392-025-02409-2openalex-snapshot
Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02)
inferred← citeshttps://doi.org/10.1038/s41416-024-02766-9openalex-snapshot
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
inferred← citeshttps://doi.org/10.1038/s41523-025-00841-9openalex-snapshot
Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer
inferred← citeshttps://doi.org/10.1038/s41571-025-01016-yopenalex-snapshot
HER2 testing: evolution and update for a companion diagnostic assay
inferred← citeshttps://doi.org/10.1038/s41598-025-08491-4openalex-snapshot
CD55 may be a new target for colorectal cancer treatment
inferred← citeshttps://doi.org/10.1038/s41698-025-01209-9openalex-snapshot
HER2 expression in breast cancer: evidence gaps and challenges
inferred← citeshttps://doi.org/10.1080/10717544.2026.2645769openalex-snapshot
Extracellular payload release from non-internalizing antibody–drug conjugates: mechanisms and linker technologies
inferred← citeshttps://doi.org/10.1080/14712598.2023.2285996openalex-snapshot
The endosomal-lysosomal system in ADC design and cancer therapy
inferred← citeshttps://doi.org/10.1080/14756366.2026.2638027openalex-snapshot
Mislocalisation of FLT3-ITD receptor contributes to MV4-11 leukaemia cell resistance to antibody-drug conjugate
inferred← citeshttps://doi.org/10.1080/14796694.2024.2354162openalex-snapshot
Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes
inferred← citeshttps://doi.org/10.1093/oncolo/oyaf228openalex-snapshot
The adverse event of interstitial lung disease in patients treated with antibody–drug conjugates
inferred← citeshttps://doi.org/10.1093/procel/pwag002openalex-snapshot
Multi-omics analysis reveals comprehensive aberrant protein and phosphorylation characteristics in breast cancer and paired metastatic lymph nodes
inferred← citeshttps://doi.org/10.1126/sciadv.aee4052openalex-snapshot
Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177 Lu-labeled HER2 Fab radioconjugate
inferred← citeshttps://doi.org/10.1136/jcp-2023-209055openalex-snapshot
Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-24-1525openalex-snapshot
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-24-1779openalex-snapshot
Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-25-3103openalex-snapshot
Predictive Biomarkers of Antibody–Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-23-0091openalex-snapshot
ADCs or: How I Learned to Stop Worrying and Love Chemotherapy
inferred← citeshttps://doi.org/10.1159/000553142openalex-snapshot
Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy
inferred← citeshttps://doi.org/10.11648/j.ijcocr.20251004.18openalex-snapshot
Mechanistic Investigation of Resistance to SHR-A1811 and T-DXd, the Third Generation of HER2-ADC, in Breast Cancer
inferred← citeshttps://doi.org/10.1177/11795549241260418openalex-snapshot
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
inferred← citeshttps://doi.org/10.1177/17588359241297079openalex-snapshot
Antibody–drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1177/17588359241311379openalex-snapshot
Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
inferred← citeshttps://doi.org/10.1186/s12885-025-14225-6openalex-snapshot
Organ-specific cancer biomarker identification: a ten-year single-center study in southern China
inferred← citeshttps://doi.org/10.1186/s12943-025-02489-2openalex-snapshot
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
inferred← citeshttps://doi.org/10.1186/s12943-026-02711-9openalex-snapshot
Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice
inferred← citeshttps://doi.org/10.1186/s13045-025-01752-9openalex-snapshot
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
inferred← citeshttps://doi.org/10.1186/s13045-026-01799-2openalex-snapshot
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming
inferred← citeshttps://doi.org/10.1186/s13045-026-01839-xopenalex-snapshot
Current and future therapies for triple-negative breast cancer
inferred← citeshttps://doi.org/10.1186/s13046-024-03143-3openalex-snapshot
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
inferred← citeshttps://doi.org/10.1186/s40164-025-00632-9openalex-snapshot
Antibody-drug conjugates in breast cancer: current evidence and future directions
inferred← citeshttps://doi.org/10.1186/s40364-024-00633-6openalex-snapshot
Trop2-targeted therapy in breast cancer
inferred← citeshttps://doi.org/10.1186/s40364-024-00654-1openalex-snapshot
Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era
inferred← citeshttps://doi.org/10.1186/s43556-025-00352-wopenalex-snapshot
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
inferred← citeshttps://doi.org/10.12677/acm.2025.1551545openalex-snapshot
Progress of Antibody Drug Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.12677/acm.2025.1571979openalex-snapshot
The Mechanism and Research Progress of Antibody-Drug Conjugates in the Treatment of Bladder Tumors
inferred← citeshttps://doi.org/10.20517/cdr.2024.180openalex-snapshot
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
inferred← citeshttps://doi.org/10.20517/cdr.2025.148openalex-snapshot
Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies
inferred← citeshttps://doi.org/10.20517/cdr.2025.195openalex-snapshot
TROP2-targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms
inferred← citeshttps://doi.org/10.20517/cdr.2025.49openalex-snapshot
The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy
inferred← citeshttps://doi.org/10.20538/1682-0363-2024-2-101-113openalex-snapshot
Molecular targets for metastasis-directed therapy in malignant tumors
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2023.0286openalex-snapshot
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer
inferred← citeshttps://doi.org/10.21037/tbcr-24-40openalex-snapshot
Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2922590/v1openalex-snapshot
tRF-27 competitively Binds to G3BPs and Activates MTORC1 to Enhance HER2 Positive Breast Cancer Trastuzumab Tolerance
inferred← citeshttps://doi.org/10.2147/bctt.s571054openalex-snapshot
Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.32604/or.2025.058997openalex-snapshot
Comparative assessment of antitumor effects between doxorubicin and mitochondria-targeted doxorubicin in combination with radiotherapy
inferred← citeshttps://doi.org/10.32604/or.2025.059290openalex-snapshot
Current status, hotspots, and trends in cancer prevention, screening, diagnosis, treatment, and rehabilitation: A bibliometric analysis
inferred← citeshttps://doi.org/10.3389/fcell.2025.1669592openalex-snapshot
Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1787148openalex-snapshot
Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1831465openalex-snapshot
Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions
inferred← citeshttps://doi.org/10.3389/fonc.2024.1395784openalex-snapshot
Progress in the study of antibody-drug conjugates for the treatment of cervical cancer
inferred← citeshttps://doi.org/10.3389/fonc.2025.1569897openalex-snapshot
TROP2: as a promising target in lung cancer
inferred← citeshttps://doi.org/10.3389/fonc.2025.1601808openalex-snapshot
Cardiovascular adverse effects of immunotherapy in cancer: insights and implications
inferred← citeshttps://doi.org/10.3389/fphar.2024.1340764openalex-snapshot
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
inferred← citeshttps://doi.org/10.3389/fphar.2024.1378010openalex-snapshot
Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
inferred← citeshttps://doi.org/10.3389/fphar.2024.1406351openalex-snapshot
History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region
inferred← citeshttps://doi.org/10.3389/fphar.2025.1532104openalex-snapshot
The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy
inferred← citeshttps://doi.org/10.3389/fphar.2025.1556245openalex-snapshot
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
inferred← citeshttps://doi.org/10.3389/fphar.2026.1882868openalex-snapshot
Mechanisms of resistance to antibody-drug conjugates in bladder cancer
inferred← citeshttps://doi.org/10.3390/biomedicines12030500openalex-snapshot
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers16193345openalex-snapshot
Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer
inferred← citeshttps://doi.org/10.3390/cancers17060958openalex-snapshot
Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment
inferred← citeshttps://doi.org/10.3390/cancers17071102openalex-snapshot
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies
inferred← citeshttps://doi.org/10.3390/cancers18162652openalex-snapshot
Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies
inferred← citeshttps://doi.org/10.3390/cimb48090868openalex-snapshot
Antibody–Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges
inferred← citeshttps://doi.org/10.3390/curroncol30040330openalex-snapshot
‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review
inferred← citeshttps://doi.org/10.3390/curroncol33020092openalex-snapshot
Trop2-Based Antibody–Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy
inferred← citeshttps://doi.org/10.3390/ijms241511903openalex-snapshot
Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
inferred← citeshttps://doi.org/10.3390/ijms242417631openalex-snapshot
Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
inferred← citeshttps://doi.org/10.3390/ijms26051908openalex-snapshot
Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.3390/ijms26136523openalex-snapshot
Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology
inferred← citeshttps://doi.org/10.3390/ijms27073287openalex-snapshot
Antibody–Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives
inferred← citeshttps://doi.org/10.3390/molecules28217389openalex-snapshot
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
inferred← citeshttps://doi.org/10.3390/pharmaceutics15082017openalex-snapshot
Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy
inferred← citeshttps://doi.org/10.3390/pharmaceutics17111414openalex-snapshot
Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions
inferred← citeshttps://doi.org/10.3892/or.2024.8854openalex-snapshot
Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review)
inferred← citeshttps://doi.org/10.4103/ijc.ijc_223_24openalex-snapshot
Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer
inferred← citeshttps://doi.org/10.4251/wjgo.v18.i5.116882openalex-snapshot
Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates
inferred← citeshttps://doi.org/10.51847/pp6tuutx6aopenalex-snapshot
Light-Activated TROP2-Targeted Nanotheranostics Restore ADC Sensitivity and Induce Immunogenic Cell Death in TNBC
inferred← citeshttps://doi.org/10.62347/yode5431openalex-snapshot
Sequencing of high-frequency mutated genes in breast cancer (BRCA) and associated-functions analysis
inferred← citeshttps://doi.org/10.66505/cbtt.v1i2.32openalex-snapshot
Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions
inferred← citeshttps://doi.org/10.7150/ijbs.87415openalex-snapshot
tRF-27 competitively Binds to G3BPs and Activates MTORC1 to Enhance HER2 Positive Breast Cancer Trastuzumab Tolerance
inferred← citeshttps://doi.org/10.7150/thno.116153openalex-snapshot
Engineered upconversion nanoparticles for breast cancer theranostics
showing the first 151 of 152 · page through all 152
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.